BRIEF—Takeda prepares to present from lung and hematology portfolios at ASCO

Japanese drugmaker Takeda will present data on both its investigational and marketed assets at the upcoming annual meeting of the American Society of Clinical Oncology.

Results from a Phase I/II first-in-human, open-label, multicenter study of TAK-788 will be presented orally. The ongoing study is investigating the antitumor activity and safety of TAK-788 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor EGFR exon 20 insertion mutations.

Takeda also will present three posters on the treatment of patients with ALK+ NSCLC with Alunbrig (brigatinib), and there will be further presentations in blood cancers, including from the Phase III PhALLCON trial – an ongoing efficacy study of Iclusig (ponatinib) in combination with reduced-intensity chemotherapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

Additional data from the ECHELON-1 and ECHELON-2 trials evaluating Adcetris (brentuximab vedotin) as a frontline treatment option in newly-diagnosed Stage III and IV Hodgkin lymphoma and in CD30+ peripheral T-cell lymphoma, respectively, will also be shared in partnership with Seattle Genetics.